Ambroxol Reneval, tablets 30 mg 20 pcs

Ambroxol is an active N-demethylated metabolite of bromhexine.

It has secretomotor, secretolytic and expectorant action.

It stimulates bronchial glands activity, increases motor activity of the syncytial epithelium by means of influence on type 2 pneumocytes in alveoli and Clara cells in bronchioles, increases formation of endogenous surfactant – a surfactant providing bronchial secretion gliding in the airway lumen.

Ambroxol increases the proportion of the serous component in bronchial secretion, improving its structure and contributing to a decrease in viscosity and liquefaction of sputum; as a result, mucociliary transport is improved and the removal of sputum from the bronchial tree is facilitated.

On average when taken orally the action of the drug comes within 30 minutes, duration of action – 6-12 hours, depending on the dose taken.

Indications

Active ingredient

Composition

How to take, the dosage

Overly, after meals, with plenty of fluids.

Adults and children over 12 years of age: 30 mg (1 tablet) 3 times a day for the first 2-3 days, then the dose should be reduced to 1 tablet 2 times a day.

Children 6 to 12 years of age: 15 mg (1/2 tablet) 2 to 3 times a day.

If symptoms persist for 4-5 days from the start of therapy, it is recommended to see a doctor.

Interaction

Special Instructions

Contraindications

Hypersensitivity to the components of the drug, hereditary galactose intolerance, lactase deficiency or glucose and galactose malabsorption syndrome, I trimester of pregnancy and breastfeeding period, children under 6 years.

With caution:

Bronchial motility disorder and increased mucus secretion (e.g., in rare primary ciliary dyskinesia syndrome); renal failure and/or severe liver failure); gastric and duodenal ulcer, including a history; II-III trimesters of pregnancy.

Side effects

Classification of the frequency of side effects according to the recommendations of the World Health Organization (WHO):

Very common > 1/10; common > 1/100 to < 1/10; infrequent > 1/1000 to < 1/100; rare > 1/10000 to < 1/1000; very rare < 1/10000, including individual reports; frequency unknown – the incidence cannot be determined from available data.

Allergic reactions:

frequency unknown – hypersensitivity reactions, anaphylactic reactions (including anaphylactic shock), angioedema.

Disorders of the digestive system:

often – nausea, decreased sensitivity in the mouth or pharynx; infrequent – dyspepsia, vomiting, diarrhea, abdominal pain; rarely – heartburn, dryness of the mucous membrane of the mouth and pharynx, constipation.

Respiratory system disorders:

rarely – dryness of the mucous membrane of the respiratory tract, rhinorrhea (discharge of mucus from the nose).

Skin disorders:

seldom – skin rash, urticaria; frequency unknown – skin itching, Stevens-Johnson syndrome (erythema multiforme), Lyell syndrome (toxic epidermal necrolysis), acute generalized exanthematous pustulosis.

Sensory system disorders:

infrequent – dysgeusia (taste disturbances).

Other:

rarely – weakness, headache, dysuria (disorders of urination), hyperthermia, fever.

Overdose

Pregnancy use

Similarities